Introduction: As part of the development of the evidence-based (S3) clinical practice guidelines for kidney and bladder cancer by the German Guideline Program in Oncology, quality indicators (QIs) were defined to measure the quality of care. Based on these guidelines and QIs, the German Cancer Society (DKG) developed two new certification systems. The aim of this article is to show the process of development and implementation of QIs in certified cancer centres. Methods: Based on strong recommendations of each guideline and an additional systematic literature review for national and international QIs, two sets of QIs were derived in a multistep standardized approach. These QIs were implemented in the centres in certification data sheets to measure their outcomes. First results of treatment years 2018 and 2019 are available. Results: The final sets include 9 QIs for kidney cancer and 12 QIs for bladder cancer. Two-thirds of the QIs were transferred to the data sheets. In 2018 and 2019, the results of all but one QI are within the plausibility limits. From 2020 on, they are replaced by stricter target values that will challenge centres to improve their outcomes. Conclusions: Guideline-derived QIs make relevant aspects of patient care measurable and consequently improvable. The first QI results are encouraging. However, the DKG certification system and the methods of measuring quality are under ongoing development. Systematic QI implementation and evaluation may help to generate broader databases and thus expand knowledge.

Keywords:
Quality indicators, Certification, Kidney cancer, Bladder cancer, Guidelines
1.
Robert Koch-Institut (RKI)
.
Krebs in Deutschlandfür 2015/2016
.
Berlin
:
RKI
.
2019
.
2.
Adam
 
H
,
Sibert
 
NT
,
Bruns
 
J
,
Wesselmann
 
S
.
Krebspatienten qualitätsgesichert, multidisziplinär und evidenzbasiert versorgen: das Zertifizierungssystem der Deutschen Krebsgesellschaft
.
BARMER Gesundheitswesen aktuell
.
2018
:
136
–
55
.
Google Scholar
 
3.
Mensah
 
J
,
Graeven
 
U
,
Wesselmann
 
S
.
Nationales Zertifizierungsprogramm Krebs
.
Onkologe
.
2017
;
23
(
9
):
711
–
8
.
https://doi.org/10.1007/s00761-017-0272-0
.
Google Scholar
Crossref
Search ADS
 
4.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF)
.
Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie. Version 2.1. [online]
;
2017
[visited: 2020 Dec 4]; Available from: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Methodik/QIEP_OL_2017_Version_2.1.pdf.
5.
Langer
 
T
,
Wesselmann
 
S
,
Kowalski
 
C
.
Qualitätsindikatoren in der Onkologie
.
Onkol Heute
.
2017
;
4
:
52
–
3
.
Google Scholar
 
6.
Langendam
 
MW
,
Piggott
 
T
,
Nothacker
 
M
,
Agarwal
 
A
,
Armstrong
 
D
,
Baldeh
 
T
,  
Approaches of integrating the development of guidelines and quality indicators: a systematic review
.
BMC Health Serv Res
.
2020
;
20
(
1
):
875
.
https://doi.org/10.1186/s12913-020-05665-w
.
Google Scholar
Crossref
Search ADS
PubMed
 
7.
Nothacker
 
M
,
Stokes
 
T
,
Shaw
 
B
,
Lindsay
 
P
,
Sipilä
 
R
,
Follmann
 
M
,  
Reporting standards for guideline-based performance measures
.
Implement Sci
.
2016
;
11
:
6
.
https://doi.org/10.1186/s13012-015-0369-z
.
Google Scholar
Crossref
Search ADS
PubMed
 
8.
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)
.
AWMF-Regelwerk Leitlinien: Graduierung der Empfehlungen. [online]
;
2020
[visited: 2020 Dec 4]; Available from: https://www.awmf.org/leitlinien/awmf-regelwerk/ll-entwicklung/awmf-regelwerk-03-leitlinienentwicklung/ll-entwicklung-graduierung-der-empfehlungen.html.
9.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF)
.
Leitlinienreport der S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms. Langversion 1.0 – September 2016. AWMF-Registernummer: 032/038OL. [online]
;
2020
[visited: 2020 Dec 4]; Available from: https://www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom.
10.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF)
.
Leitlinienreport S3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms. Version 1.0 – September 2015. AWMF-Registernummer: 043/017OL. [online]
;
2020
[visited: 2020 Dec 4]; Available from: https://www.leitlinienprogramm-onkologie.de/leitlinien/nierenzellkarzinom.
11.
Deutsche Krebsgesellschaft (DKG), OnkoZert
.
Uroonkologische Zentren. Auditjahr 2020. Datenblatt Modul Niere. [online]
;
2020
[visited: 2020 Dec 10]; Available from: https://www.onkozert.de/uro.
12.
Deutsche Krebsgesellschaft (DKG), OnkoZert
.
Uroonkologische Zentren. Auditjahr 2020. Datenblatt Modul Harnblase. [online]
;
2020
[visited: 2020 Dec 10]; Available from: https://www.onkozert.de/uro.
13.
Deutsche Krebsgesellschaft (DKG)
.
Jahresberichte Organkrebszentren. [online]
;
2020
[visited: 2020 Jan 1]; Available from: https://www.krebsgesellschaft.de/jahresberichte.html.
14.
Royal Free London NHS Foundation Trust
.
Quality Performance Indicators Kidney Cancer. [online]
;
2013
[visited: 2020 Dec 4]; Available from: http://www.londoncancer.org/media/61502/quality-performance-indicators-010813.pdf.
15.
Scottish Cancer Taskforce, National Cancer Quality Steering Group
.
Renal Cancer. Clinical Quality Performance Indicators August 2017 (v3.1). [online]
; 2012 July 2019 [visited: 2020 Dec 10]; Available from: http://www.healthcareimprovementscotland.org/our_work/cancer_care_improvement/cancer_qpis/quality_performance_indicators.aspx.
16.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF)
.
S3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms. Langversion 2.0 – August 2020. AWMF-Registernummer: 043/017OL. [online]
;
2020
[visited: 2020 Dec 4]; Available from: https://www.leitlinienprogramm-onkologie.de/leitlinien/nierenzellkarzinom.
17.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF)
.
S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms. Langversion 2.0 – März 2020. AWMF-Registernummer: 032/038OL. [online]
;
2020
[visited: 2020 Dec 4]; Available from: https://www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom.
18.
Deutsche Krebsgesellschaft, OnkoZert
.
OnkoMap – Liste der zertifizierten Krebszentren. [online]
;
2020 Dec 12
[visited: 2020 Dec 4]; Available from: https://www.oncomap.de.
19.
Breidenbach
 
C
,
Sibert
 
NT
.
Neues aus der Patientenperspektive – das Projekt EDIUM läuft an
.
Forum
.
2018
;
33
(
5
):
308
–
11
.
https://doi.org/10.1007/s12312-018-0483-3
.
Google Scholar
Crossref
Search ADS
 
20.
Kowalski
 
C
,
Wesselmann
 
S
.
Ergebnisqualität messen und vergleichen
.
Onkol Heute
.
2017
;
2
:
28
–
9
.
Google Scholar
 
21.
Butea-Bocu
 
MC
,
Muller
 
G
,
Pucheril
 
D
,
Kroger
 
E
,
Otto
 
U
.
Is there a clinical benefit from prostate cancer center certification? An evaluation of functional and oncologic outcomes from 22,649 radical prostatectomy patients
.
World J Urol
.
2020
;
39
(
1
):
5
–
10
.
Google Scholar
Crossref
Search ADS
PubMed
 
22.
Follmann
 
M
,
Eigentler
 
T
,
Adam
 
H
,
Wenzel
 
G
,
Langer
 
T
,
Wesselmann
 
S
.
Quality assurance in melanoma care: guideline-based quality indicators for melanoma – implementation, evaluation and update process
.
J Dtsch Dermatol Ges
.
2020
;
18
(
8
):
848
–
57
.
Google Scholar
 
23.
Beckmann
 
MW
,
Brucker
 
C
,
Hanf
 
V
,
Rauh
 
C
,
Bani
 
MR
,
Knob
 
S
,  
Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients
.
Onkologie
.
2011
;
34
(
7
):
362
–
7
.
https://doi.org/10.1159/000329601
.
Google Scholar
Crossref
Search ADS
PubMed
 
24.
Volkel
 
V
,
Draeger
 
T
,
Gerken
 
M
,
Furst
 
A
,
Klinkhammer-Schalke
 
M
.
Langzeitüberleben von Patienten mit Kolon- und Rektumkarzinomen: Ein Vergleich von Darmkrebszentren und nicht zertifizierten Krankenhäusern
.
Gesundheitswesen
.
2019
;
81
(
10
):
801
–
7
.
Google Scholar
Crossref
Search ADS
PubMed
 
25.
Greger
 
B
,
Altendorf-Hofmann
 
A
,
Kletzke
 
K
.
Improved outcome in certified colorectal cancer centers in a German county. 33. Deutscher Krebskongress – Perspektiven verändern Krebs – Krebs verändert Perspektiven. Diagnose – Therapie – (Über-) Leben. Berlin, 21.-24 February 2018: abstracts
.
Oncol Res Treat
.
2018
;
41
(
Suppl 1
):
186
.
Google Scholar
 
26.
Haj
 
A
,
Doenitz
 
C
,
Schebesch
 
KM
,
Ehrensberger
 
D
,
Hau
 
P
,
Putnik
 
K
,  
Extent of resection in newly diagnosed glioblastoma: impact of a specialized neuro-oncology care center
.
Brain Sci
.
2017
;
8
(
1
).
https://doi.org/10.3390/brainsci8010005
.
Google Scholar
 
27.
Kreienberg
 
R
,
Wöckel
 
A
,
Wischnewsky
 
M
.
Highly significant improvement in guideline adherence, relapse-free and overall survival in breast cancer patients when treated at certified breast cancer centres: an evaluation of 8323 patients
.
Breast
.
2018
;
40
:
54
–
9
.
https://doi.org/10.1016/j.breast.2018.04.002
.
Google Scholar
Crossref
Search ADS
PubMed
 
28.
Trautmann
 
F
,
Reissfelder
 
C
,
Pecqueux
 
M
,
Weitz
 
J
,
Schmitt
 
J
.
Evidence-based quality standards improve prognosis in colon cancer care
.
Eur J Surg Oncol
.
2018
;
44
(
9
):
1324
–
30
.
https://doi.org/10.1016/j.ejso.2018.05.013
.
Google Scholar
Crossref
Search ADS
PubMed
 
29.
Hoffmann
 
H
,
Passlick
 
B
,
Ukena
 
D
,
Wesselmann
 
S
.
Mindestmengen in der Thoraxchirurgie: Argumente aus der deutschen DRG-Statistik
. In:
Dormann
 
F
,
Klauber
 
J
,
Kuhlen
 
R
, editors.
Qualitätsmonitor 2018
.
Berlin
:
Medizinisch Wissenschaftliche Verlagsgesellschaft
;
2018
. p.
103
–
20
.
Google Scholar
 
30.
Weinhold
 
I
,
Keck
 
T
,
Merseburger
 
A
,
Rody
 
A
,
Wollenberg
 
B
,
Wende
 
D
,  
Nutzenanalyse onkologischer Zentrenbildung im Bereich der Behandlung des kolorektalen Karzinoms
.
Zentralbl Chir
.
2018
;
143
(
2
):
181
–
92
.
https://doi.org/10.1055/s-0042-122854
.
Google Scholar
Crossref
Search ADS
PubMed
 
31.
Rückher
 
J
,
Wesselmann
 
S
,
Seufferlein
 
T
,
Darmkrebszentren
 
Z
.
Ein Beitrag zur Verbesserung der Versorgungsqualität
.
Der Onkologe
;
2020
;
27
(
Suppl 1
).
Google Scholar
 
© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.